Morningstar

GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

MENLO PARK, Calif., Jan. 29, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the submission of the ...
Nasdaq

GRAIL Submits FDA Premarket Approval Application For The Galleri MCED Test

(RTTNews) - GRAIL Inc. (GRAL), a healthcare company, announced the submission of the final module of the Premarket Approval or PMA application to the U.S. Food and Drug Administration or FDA for its ...
MarketWatch

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT(R) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

The MarketWatch News Department was not involved in the creation of this content. - Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular ...
Hosted on MSN

Artivion secures FDA approval for NEXUS aortic arch system

Artivion, Inc. AORT recently announced that the FDA has approved the premarket approval application for the NEXUS Aortic Arch System. Developed in partnership with Endospan Ltd., this innovative ...
Seeking Alpha

GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

FDA Submission Marks a Pivotal Milestone in Advancing Early Cancer Detection, Addressing Unmet Needs in Cancer Screening MENLO PARK, Calif., Jan. 29, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a ...
Nasdaq

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

- Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from the FDA as each module is submitted - - Module submitted in parallel to ...